苯磺酸左旋氨氯地平片联合脂必泰治疗糖尿病合并冠心病痰瘀交阻证的临床疗效观察

摘要目的：观察苯磺酸左旋氨氯地平片联合脂必泰胶囊治疗糖尿病合并冠心病痰瘀交阻证的临床疗效。方法：120例糖尿病性冠心病痰瘀交阻证患者随机分为两组，均给与注射胰岛素控制血糖。对照组（n=60）给与阿托伐他汀10mg，每日1次口服。治疗组（n=60）给与苯磺酸左旋氨氯地平片5mg，每天1次口服；脂必泰胶囊1粒，每天2次口服。两组均治疗3个月。分析比较治疗前后空腹血糖（FBG）、总胆固醇（TC）等指标，心电图（ECG），并记录中医症状积分。结果：治疗组总有效率86．67％，对照组总有效率51．67％，两组相比较，差异有显著性（P〈0．01）。两组空腹血糖（VBO）、糖化血红蛋白（HbAlc）、甘油三酯（TO）等指标治疗后与治疗前比较，差异有统计学意义（P〈0．05或P〈0．01）。治疗后治疗组总胆固醇（TC）、高密度脂蛋白（HDL．C）与对照组相比较，变化显著（P〈0．05）。治疗组中医症状积分下降较对照组明显（P〈O．05或P〈0．01）。结论：苯磺酸左旋氨氯地平片联合脂必泰胶囊治疗糖尿病性冠心病痰瘀交阻证疗效确切。

Clinical Effect of Levamlodipine Besylate Tablet Combined with Zhibitai Capsule in Treating Diabetic Coronary Heart Disease with Phlegm-stasis Retention Syndrome

Objective： To observe the effect ofLevamlodipine besylate tablet combined with Zhibitai capsule on diabetic coronary heart disease（D-CHD）with phlegm-stasis retention syndrome. Methods： A total 120 D-CHD patients with phlegm-stasis retention syndro- me were divided randomly into two groups. Both groups were treated by the insulin injection to lower blood sugar. The control group （n=60）was also given atorvastatin 10mg qd po, while the treatment group（n=60）was given Levamlodipine besylate tablet 5mg qd po, and Zhibitai capsule one capsule bid po. After 3 months of treatment, the indicators such as the levels of FBG, TG and so on, electrocardiogram （ECG） and TCM symptoms scores were detected and compared. Results： The total effective rate of treatment group was 86.67%, that of control group was 51.67%; there was significant difference between the two groups （P〈0.01）. After treatment, the levels ofFBG, HbAlc, TG, TC in both groups were lower after treatment than that of before treatment （P〈0.05 or P〈0.01）. HDL-C and TC of the treatment group after treatment showed significant difference with those of the control group （P〈0.05）. TCM symptom scores were also lowered significantly in treatment group（P〈0.05 or P〈0.01）. Conclusion： Levamlodipine besylate tablet combined with Zhibitai capsule has reliable clinical effect on diabetic coronary heart disease with phlegrn-stasis retention syndrome.